Breaking News
Subscribe Now 0
🧐 ProPicks AI October update is out now! See which stocks made the list Pick Stocks with AI
Close

Roche Holding AG (0QQ6)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
278.20 -25.60    -8.43%
04/10 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  CH0012032113 
SEDOL:  BKJ8Y02
  • Volume: 240
  • Bid/Ask: 275.00 / 0.00
  • Day's Range: 278.20 - 282.60
Roche Holding 278.20 -25.60 -8.43%

0QQ6 Recent Sentiments

 
This page contains information on users’ sentiments for the Roche Holding AG stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
Jun 17, 2024 Stepan Shakhno   270.80 Jul 12, 2024 @ 281.80 +4.06%
Jun 17, 2024 Ab Di   270.80 Jun 24, 2024 @ 277.39 +2.43%
Apr 10, 2024 Feng Hanji   239.20 May 03, 2024 @ 234.80 -1.84%
Feb 20, 2024 Igor Mavriky   247.00 Mar 15, 2024 @ 243.00 -1.62%
Oct 17, 2023 Maynard Grout   307.60 Nov 30, 2023 @ 307.60 0.00%
May 31, 2023 massimo ferrario   315.60 Nov 30, 2023 @ 307.60 -2.53%
Mar 31, 2023 Lilia Litvin   275.40 Apr 21, 2023 @ 302.02 -9.67%
Mar 30, 2023 Sebastiaan Seghers   270.80 Apr 03, 2023 @ 273.20 +0.89%
Mar 07, 2023 Sebastiaan Seghers   287.80 Mar 13, 2023 @ 279.54 -2.87%
Feb 15, 2023 Sebastiaan Seghers   302.20 Feb 20, 2023 @ 297.00 -1.72%
Nov 17, 2022 Mitsi Roussopoulou   364.80 Dec 09, 2022 @ 372.60 +2.14%
Jun 16, 2022 Willem Wessels   348.20 Jul 08, 2022 @ 379.60 +9.02%
Apr 27, 2022 Willem Wessels   390.00 May 20, 2022 @ 359.20 -7.90%
Nov 11, 2020 Willem Wessels   314.40 Dec 04, 2020 @ 303.80 +3.37%
Nov 04, 2020 Оксана Бахтина   315.20 Nov 27, 2020 @ 301.40 -4.38%
Nov 03, 2020 Willem Wessels   304.40 Nov 03, 2020 @ 304.40 0.00%
Oct 08, 2020 Harry Cooke   316.60 Oct 30, 2020 @ 295.40 -6.70%
Oct 02, 2020 Ivaylo Yordanov   316.60 Oct 23, 2020 @ 298.60 +5.69%
Sep 16, 2020 Pat Macharon   336.20 Oct 09, 2020 @ 320.80 -4.58%
Jul 13, 2020 Shobeir Mirkhan   331.40 Aug 07, 2020 @ 316.00 -4.65%
Jul 03, 2020 Andrea Bucca   325.37 Jul 24, 2020 @ 317.60 -2.39%
Jun 25, 2020 Wild Cat   329.70 Jul 17, 2020 @ 337.00 +2.21%
May 22, 2020 ahmet akkoc   342.20 Jun 12, 2020 @ 325.60 -4.85%
May 19, 2020 Robin Chittilapilly   348.64 May 25, 2020 @ 345.60 -0.87%
May 18, 2020 aji koo   351.60 Jun 12, 2020 @ 325.60 -7.39%
May 14, 2020 Darren Price   349.80 Jun 05, 2020 @ 330.80 -5.43%
May 11, 2020 Daniel Smith   342.24 Jun 05, 2020 @ 330.80 -3.34%
May 04, 2020 Harry Cooke   335.20 May 22, 2020 @ 343.40 +2.45%
Mar 17, 2020 Richard Dodds   288.60 Mar 18, 2020 @ 287.20 -0.49%
Mar 13, 2020 Saif Bayoumi   292.20 Apr 03, 2020 @ 319.40 +9.31%
Mar 12, 2020 GALLI Antonio   279.60 Apr 03, 2020 @ 319.40 +14.23%
Feb 14, 2020 Foyin Olufemi   337.60 Mar 06, 2020 @ 310.20 -8.12%
Oct 30, 2019 Foyin Olufemi   291.80 Nov 22, 2019 @ 300.15 +2.86%
Oct 21, 2019 nick fink   287.40 Nov 15, 2019 @ 293.38 +2.08%
Dec 21, 2017 Artis_1   18564.53 Jan 20, 2018 @ 17982.43 +3.14%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joe Jordan
Joe Jordan May 21, 2024 5:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Joe Jordan
Joe Jordan May 21, 2024 5:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Lee John
Lee John Nov 16, 2020 3:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just like Biolidics. they get approval for Covid19 tests kits in USA
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is the historical price adjusted for stock splits?
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email